High platelet reactivity tied to ischemic, bleeding outcomes

August 16, 2017

(HealthDay)—There is a strong relationship between high on-clopidogrel platelet reactivity and two-year ischemic and bleeding outcomes after drug-eluting stent implantation, according to a study published online Aug. 2 in JACC: Cardiovascular Interventions.

Thomas D. Stuckey, M.D., from Cone Health in Greensboro, N.C., and colleagues analyzed two-year outcomes in the Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents study, which followed 8,582 patients undergoing routine platelet function testing following with drug-eluting (2008 to 2010).

The researchers found that 46.3 percent of patients were on dual antiplatelet therapy at two years without discontinuation. Ninety-two patients (1.07 percent) had definite or probable stent thrombosis at two years. High platelet reactivity on clopidogrel was independently associated with definite or probable stent thrombosis in continuously treated patients (hazard ratio [HR], 2.09; 95 percent confidence interval [CI], 1.29 to 3.82; P = 0.006). Other associations included myocardial infarction (HR, 1.33; 95 percent CI, 1.04 to 1.71; P = 0.02), freedom from clinically relevant bleeding (HR, 0.78; 95 percent CI, 0.64 to 0.94; P < 0.01), and all-cause mortality (adjusted HR, 1.35; 95 percent CI, 1.00 to 1.84, P = 0.05).

"Aspirin hypo-responsiveness in low-risk patients maintained on aspirin monotherapy beyond one year did not predict late events. High reactivity in high-risk maintained on dual antiplatelet therapy was independently associated with outcomes to two years," the authors write. "Future studies evaluating the long-term use of adenosine diphosphate inhibition should incorporate individualized patient selection to optimize the trade-off between ischemic event reduction and bleeding."

Several authors disclosed financial ties to medical device and pharmaceutical companies, several of which funded the study.

Explore further: 1-year results of ADAPT-DES trial published in The Lancet

More information: Abstract/ Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

1-year results of ADAPT-DES trial published in The Lancet

July 26, 2013
Patients who receive a drug-eluting stent (DES) and demonstrate high platelet reactivity on clopidogrel are more likely to have blood clots form on the stent and to suffer a heart attack; however, these patients are less ...

Study: AHA guidelines to treating patients with coronary artery disease

June 27, 2017
The most recent dual antiplatelet guidelines from the American Heart Association and the American College of Cardiology encourage healthcare providers to take a customized approach to treating patients with coronary artery ...

Risk up for triple Tx versus DAPT in DES implantation with A-fib

May 23, 2017
(HealthDay)—For patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES), atrial fibrillation (AF) is associated with increased risks, with no benefit and higher risk seen for triple therapy ...

Anemia independently linked to high platelet reactivity in PCI

June 9, 2016
(HealthDay)—Anemia is independently associated with high platelet reactivity (HPR) and is associated with all-cause mortality and major bleeding after percutaneous coronary intervention with drug-eluting stents, according ...

30-day results of ADAPT-DES registry reported at TCT 2011

November 9, 2011
The relationship of platelet responsiveness to antiplatelet medications; and, the correlation of poor response, and overall platelet aggregation while on dual antiplatelet therapy to the risk of drug-eluting stent thrombosis ...

Low responsiveness to clopidogrel predicts stent thrombosis, heart attack: But is not directly linked to death

October 25, 2012
Patients who receive a drug-eluting stent (DES) and demonstrate low levels of platelet inhibition are more likely to have blood clots form on the stent and suffer a possible heart attack; conversely, patients with higher ...

Recommended for you

Metabolism switch signals end for healing hearts

September 19, 2017
Researchers have identified the process that shuts down the human heart's ability to heal itself, and are now searching for a drug to reverse it.

Beta blockers not needed after heart attack if other medications taken

September 18, 2017
A new study from the University of North Carolina at Chapel Hill finds beta blockers are not needed after a heart attack if heart-attack survivors are taking ACE inhibitors and statins. The study is the first to challenge ...

Which single behavior best prevents high blood pressure?

September 15, 2017
(HealthDay)—You probably already know that certain healthy lifestyle behaviors can reduce your risk of developing high blood pressure, but is any one behavior more important than the others?

RESPECT trial shows closing a small hole in heart may protect against recurrent stroke

September 13, 2017
A device used to close a small hole in the heart may benefit certain stroke patients by providing an extra layer of protection for those facing years of ongoing stroke risk, according to the results of a large clinical trial ...

Study shows so-called 'healthy obesity' is harmful to cardiovascular health

September 11, 2017
Clinicians are being warned not to ignore the increased cardiovascular health risks of those who are classed as either 'healthy obese' or deemed to be 'normal weight' but have metabolic abnormalities such as diabetes.

Statins reduce deaths from heart disease by 28 percent in men with high LDL levels, says longest ever study

September 6, 2017
Previous research has shown the benefit of statins for reducing high cholesterol and heart disease risk amongst different patient populations. However, until now there has been no conclusive evidence from trials for current ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.